NovelStem International Corp.
NovelStem International Corp. Fundamental Analysis
NovelStem International Corp. (NSTM) shows weak financial fundamentals with a PE ratio of 0.20, profit margin of 0.00%, and ROE of -82.70%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -54.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze NSTM's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNSTM demonstrates superior asset utilization.
Valuation Score
ExcellentNSTM trades at attractive valuation levels.
Growth Score
ModerateNSTM shows steady but slowing expansion.
Financial Health Score
ModerateNSTM shows balanced financial health with some risks.
Profitability Score
WeakNSTM struggles to sustain strong margins.
Key Financial Metrics
Is NSTM Expensive or Cheap?
P/E Ratio
NSTM trades at 0.20 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NSTM's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values NovelStem International Corp. at -0.22 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.45 times EBITDA. This is generally considered low.
How Well Does NSTM Make Money?
Net Profit Margin
For every $100 in sales, NovelStem International Corp. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-82.70 in profit for every $100 of shareholder equity.
ROA
NovelStem International Corp. generates $150.77 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
NSTM converts -33.07% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.20
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.001
vs 25 benchmark
P/B Ratio
Price to book value ratio
-0.22
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.81
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.008
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.83
vs 25 benchmark
ROA
Return on assets percentage
150.77
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How NSTM Stacks Against Its Sector Peers
| Metric | NSTM Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.20 | 28.45 | Better (Cheaper) |
| ROE | -82.70% | 763.00% | Weak |
| Net Margin | 0.00% | -45265.00% (disorted) | Weak |
| Debt/Equity | -0.81 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 0.01 | 2795.60 | Weak Liquidity |
| ROA | 15077.27% | -16588.00% (disorted) | Strong |
NSTM outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews NovelStem International Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-426.45%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-157.56%
Industry Style: Defensive, Growth, Innovation
Declining